Saturday, July 11, 2026

pharma · Duchenne Muscular Dystrophy · Muscular Dystrophies · CAPR

CAPRICOR THERAPEUTICS

CAPRICOR THERAPEUTICS is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker CAPR. Primary therapeutic focus areas include Duchenne Muscular Dystrophy, Muscular Dystrophies, Covid19, Dil

San Diego, USA HQ
2005 Founded
240 Employees
Public company Type
CAPR · NYSE Ticker
Company details
Status
Public
HQ
San Diego, USA
Founded
2005
Employees
240
Programs
8
Drugs
6
Patents
43
Clinical program

Cenderitide

Phase 2 · small molecule · Heart Failure

Cenderitide for Heart Failure is a Phase 2 program (small_molecule) at CAPRICOR THERAPEUTICS, INC. with 2 ClinicalTrials.gov record(s).

← All CAPRICOR THERAPEUTICS, INC. projects Phase 2 small molecule completed

Internal code CDNP-578-02

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
CAPRICOR THERAPEUTICS, INC.
Phase
Phase 2
Modality
small_molecule
Indication
Heart Failure
Status
completed
Trials
2

Clinical trials